Reacción a "Administering immunotherapy and chemotherapy in the morning could improve their effectiveness against lung cancer"

This article marks a turning point, as it provides the first evidence that administering immunotherapy in the afternoon has a modulating effect on the adaptive immune system, specifically on T cells.

A non-causal association was already known; now that causality has been established in this study. The immediate implications are to move a large part of immunotherapy treatments to the afternoon. This study establishes this connection, but it remains to be explored whether it is solely the administration of the drug in the morning or whether there are other determinants in this specific cohort of patients that also contribute to the response."

Are there any important limitations to consider?

‘Yes, the number of patients (210), as well as the extrapolation to other types of tumours. It is an extremely provocative study, which will undoubtedly motivate new trials along these lines to identify whether we can establish biomarkers to know which patients can benefit from the timing of immunotherapy administration.’,